Mari Dugas

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised VNGR Beverage (doing business as poppi), a fast-growing prebiotic soda brand, on its acquisition by PepsiCo (Nasdaq: PEP) for $1.95 billion, including an additional potential earnout consideration subject to the achievement of certain performance milestones within a specified period after closing.

Cooley advised Baseten, the top inference platform for artificial intelligence (AI)-native products, on its $75 million Series C financing, bringing its total funding to $135 million.